Sodium–glucose cotransporter 2 inhibitor‐induced changes in body composition and simultaneous changes in metabolic profile: 52‐week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Aims/Introduction: It is unclear how changes in body composition induced by sodium–glucose cotransporter 2 (SGLT 2) inhibitor treatment correlate with metabolic profile changes. We aimed to clarify how metabolic profile changes correlate with body component changes, and if SGLT 2 inhibitor treatment causes sarcopenia and bone mineral content (BMC) loss. Materials and Methods: Moderately obese Japanese type 2 diabetes patients, treated with luseogliflozin for a year, were observed prospectively and evaluated for body composition changes. We analyzed the changes in the individual body components during treatment, and their correlation with other clinical variables. Results: The efficacy analysis set comprised 37 of 43 enrolled patients. The total fat mass significantly decreased early in the treatment at and after week 4, with a mean decrease of −1.97 kg (95% confidence interval −2.66 to −1.28) at week 24. The visceral fat area at week 24 showed an average downward trend, although this was not significant. The changes in visceral fat area in individual patients showed a significant negative correlation with the extent of the baseline visceral fat area (r = −0.399, P = 0.023). The skeletal muscle mass index showed a significant but small change at and after week 36. The BMC profile showed a transient significant decrease only at week 12. No significant change in BMC was noted at other time‐points. Conclusions: Luseogliflozin treatment brought about favorable changes in body composition and metabolism of moderately obese Japanese type 2 diabetes patients, accompanied by body fat reduction, and minimal muscle and BMC reduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Epidemiology of Sarcopenia among the Elderly in New Mexico
Baumgartner, R. N., Koehler, K. M., Gallagher, D., Romero, L., Heymsfield, S. B., Ross, R. R., Garry, P. J., & Lindeman, R. D. (1998) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a009520 · Cited by 4,004
Association between body-mass index and risk of death in more than 1 million Asians
Zheng, W., McLerran, D. F., Rolland, B., Zhang, X., Inoue, M., Matsuo, K., He, J., Gupta, P. C., Ramadas, K., Tsugane, S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010679 · Cited by 885
Prevalence and Determinant Factors of Sarcopenia in Patients With Type 2 Diabetes
Kim, T. N., Park, M. S., Yang, S. J., Yoo, H. J., Kang, H. J., Song, W., Seo, J. A., Kim, S. G., Kim, N. H., Baik, S. H., et al. (2010) · Diabetes Care · doi:10.2337/dc09-2310 · Cited by 585
Johnson, K. C., Bray, G. A., Cheskin, L. J., Clark, J. M., Egan, C. M., Foreyt, J. P., Garcia, K. R., Glasser, S., Greenway, F. L., Gregg, E. W., et al. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3214 · Cited by 104
Cited by
Pharmacotherapy of obesity: available medications and drugs under investigation.
Pilitsi, E., Farr, O. M., Polyzos, S. A., Perakakis, N., Nolen-Doerr, E., Papathanasiou, A.-E., & Mantzoros, C. S. (2019) · Metabolism · doi:10.1016/j.metabol.2018.10.010 · Cited by 248
Sargeant, J. A., Henson, J., King, J. A., Yates, T., Khunti, K., & Davies, M. J. (2019) · Endocrinology and Metabolism · doi:10.3803/enm.2019.34.3.247 · Cited by 231
Chehrehgosha, H., Sohrabi, M. R., Ismail-Beigi, F., Malek, M., Reza Babaei, M., Zamani, F., Ajdarkosh, H., Khoonsari, M., Fallah, A. E., & Khamseh, M. E. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01011-3 · Cited by 173
Antihypertensive and Renal Mechanisms of SGLT2 (Sodium-Glucose Linked Transporter 2) Inhibitors
Wilcox, C. S. (2020) · Hypertension · doi:10.1161/hypertensionaha.119.11684 · Cited by 167
Volpe, S., Lisco, G., Fanelli, M., Racaniello, D., Colaianni, V., Lavarra, V., Triggiani, D., Crudele, L., Triggiani, V., Sabbà, C., et al. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1240263 · Cited by 73
Metadata
- Authors
- Sasaki, T., Sugawara, M., & Fukuda, M.
- Venue
- Journal of Diabetes Investigation
- Publisher
- Wiley
- Published
- 2018-05-16
- Volume
- 10
- Issue
- 1
- Pages
- 108-117
- ISSN
- 2040-1116 (ISSN-L)
- 2040-1124
- OpenAlex
- W2801524940
- Cited by
- 119
- References
- 6
- FWCI
- 8.53
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.